课题基金 / 基金详情

UT M.D. Anderson Cancer Center Lymphoma SPORE

UT M.D. Anderson Cancer Center Lymphoma SPORE
UT M.D. 安德森癌症中心淋巴瘤孢子
批准号:
8120295
负责人:
LARRY W KWAK
金额:
$47.5万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-01 至 2013-08-31

项目摘要

项目成果

LARRY W KWAK的其他基金

相似基金

相关文献

中文摘要
翻译
德克萨斯大学安德森癌症中心提出了一项卓越研究淋巴瘤专业项目(SPORE)。淋巴瘤孢子的主要目标是通过创新的治疗策略来提高淋巴瘤的治愈率,这些策略基于淋巴瘤生物学、免疫学和分子遗传学的最新发现。m.d. Anderson淋巴瘤孢子是基础和转化科学家、临床研究者、血液病理学家和生物统计学家之间的多学科合作成果,由4个研究项目和4个核心资源以及发展研究和职业发展计划组成。
英文摘要
The University of Texas M. D. Anderson Cancer Center is proposing a Lymphoma Specialized Program of Research Excellence (SPORE). The primary goal of this Lymphoma SPORE is to improve the cure rate of lymphoma through innovative therapeutic strategies based on effective and focused translation of recent discoveries in lymphoma biology, immunology, and molecular genetics. The M. D. Anderson Lymphoma SPORE is a multidisciplinary collaborative effort between basic and translational scientists, clinical investigators, hematopathologists, and biostatisticians that is organized in 4 research projects and 4 core resources, as well as programs for developmental research and career development program. The research projects listed are designed to target specific areas important in lymphoma: Project 1 - Epigenetic-based therapy of Hodgkin lymphoma (Liu/Younes) Project 2 - Development of 8-chloro-adenosine therapy (Gandhi/McLaughlin) Project 3 - Targeting MDM2/P53 in ALL (Andreeff/O'Brien) Project 4 - Gene expression profiling and pathway targeted therapy in peripheral T-cell lymphoma (Chan/Vose) Core and other resources are the following: Core A - Administrative Core B - Biospecimen Core C - Clinical Research Core D - Biostatistics and Bioinformatics Development Research Program (DRP) and Career Development Program (CDP)
期刊论文(71)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1007/s00277-013-1684-6
发表时间: 2013-06
期刊: ANNALS OF HEMATOLOGY
影响因子: 3.5
作者: [Kunkalla, Kranthi, Liu, Yadong, Qu, Changju, Leventaki, Vasiliki, Agarwal, Nitin K., Singh, Rajesh R., Vega, Francisco]
通讯作者: Vega, Francisco
DOI: 10.1038/emm.2014.105
发表时间: 2015-01-23
期刊: EXPERIMENTAL AND MOLECULAR MEDICINE
影响因子: 12.8
作者: [Cai, Qingqing, Chen, Kailin, Young, Ken H.]
通讯作者: Young, Ken H.
DOI: 10.18632/oncotarget.3479
发表时间: 2015-03-20
期刊: Oncotarget
影响因子: --
作者: [Xu-Monette ZY, Tu M, Jabbar KJ, Cao X, Tzankov A, Visco C, Nagarajan L, Cai Q, Montes-Moreno S, An Y, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Zhao X, Møller MB, Farnen JP, Winter JN, Piris MA, Miranda RN, Medeiros LJ, Young KH]
通讯作者: Young KH
DOI: 10.1016/s1470-2045(14)70455-3
发表时间: 2014-11
期刊: The Lancet. Oncology
影响因子: --
作者: [Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS]
通讯作者: Neelapu SS
36
    P1 - COMBINATION ACTIVATED T-CELL AND VACCINE THERAPY IN MYELOMA
    CAREER DEVELOPMENT PROGRAM
    Immunization of Stem Cell Transplant Donors to Enhance Graft-versus-Tumor Effect
    Immunization of Stem Cell Transplant Donors to Enhance Graft-versus-Tumor Effect
    海外基金